Edgestream Partners L.P. Has $9.25 Million Position in IDEXX Laboratories, Inc. $IDXX

Edgestream Partners L.P. lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 640.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,469 shares of the company’s stock after acquiring an additional 14,244 shares during the period. Edgestream Partners L.P.’s holdings in IDEXX Laboratories were worth $9,254,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in IDXX. Elyxium Wealth LLC bought a new position in IDEXX Laboratories in the fourth quarter valued at approximately $3,666,459,000. State Street Corp lifted its stake in IDEXX Laboratories by 4.0% during the fourth quarter. State Street Corp now owns 3,656,626 shares of the company’s stock worth $2,473,817,000 after purchasing an additional 138,956 shares during the last quarter. J. Stern & Co. LLP lifted its stake in IDEXX Laboratories by 23,694.7% during the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after purchasing an additional 2,642,200 shares during the last quarter. Geode Capital Management LLC lifted its stake in IDEXX Laboratories by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock worth $1,749,380,000 after purchasing an additional 86,263 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of IDEXX Laboratories by 13.8% in the 4th quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock valued at $1,016,296,000 after purchasing an additional 181,955 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $569.46 on Thursday. The stock has a market cap of $44.92 billion, a price-to-earnings ratio of 41.93, a P/E/G ratio of 3.12 and a beta of 1.55. IDEXX Laboratories, Inc. has a twelve month low of $518.55 and a twelve month high of $769.98. The company’s fifty day moving average is $557.25 and its 200 day moving average is $591.71. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period last year, the company earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Wall Street Analyst Weigh In

IDXX has been the topic of several recent analyst reports. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Citigroup assumed coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. Finally, UBS Group decreased their target price on IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating on the stock in a research report on Monday. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $749.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.